The overall 5 year survival rate for pancreatic ductal adenocarcinoma (ie, PDAC) is a dismal
5%, although patients that have undergone surgical resection have a somewhat better …

Pancreatic ductal adenocarcinoma (PDA) remains one of the most lethal tumor types, with
extremely low survival rates due to late diagnosis and resistance to standard therapies. A …

Pancreatic Ductal Adenocarcinoma (PDAC) remains one of the most challenging
malignancies to treat, with a complex interplay of molecular pathways contributing to its …

Background & Aims Pancreatic ductal adenocarcinoma (PDAC) is characterized by
activated pancreatic stellate cells (PSCs), abundance of extracellular matrix (ECM), and …

Background: Galectins are a group of carbohydrate-binding proteins that are involved in
neoplastic development and progression. In a previous mass spectrometry-based study, we …

Galectin-3 (Gal-3) plays a multifaceted role in the development, progression, and prognosis
of pancreatic ductal adenocarcinoma (PDAC). This review offers a comprehensive …

Abstract Background Galectins (Gal's) are a family of carbohydrate-binding proteins that are
known to support the tumour microenvironment through their immunosuppressive activity …

Despite some advances, pancreatic ductal adenocarcinoma (PDAC) remains generally
refractory to current treatments. Desmoplastic stroma, a consistent hallmark of PDAC, has …

Background Galectin-1, a member of carbohydrate-binding proteins with a polyvalent
function on tumor progression, was found strongly expressed in pancreatic satellite cells …

Abstract Purpose: Galectin-3, a member of the β-galactoside-binding lectin family, has
multiple biological functions including cell-cell interactions and cell-extracellular matrix …